---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034922"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:51:17.016826+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DiaMedica updates AIS trial protocol, delays interim readout to Q4 2025; Q3 R&D spend rises

## Summary
- Expanded ReMEDy2 trial to include thrombolytic non-responders; interim analysis sample size increased to 200 from 144.
- Top-line interim results now expected Q4 2025 (prior Summer 2025); interim analysis delayed.
- Q3 2024 R&D expenses $5.0M (up from $3.3M YoY); G&A flat at $1.9M.
- Cash, equivalents and investments $50.2M as of Sep 30, 2024; cash runway into Q3 2026.
- Preeclampsia Phase 2 IST received SAHPRA approval; first patient dosed; top-line Part 1A results expected H1 2025.

## SEC filing metadata
- accession: 0001437749-24-034922
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774924034922/0001437749-24-034922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774924034922/dmtp20241113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034922
- JSON: https://secwatch.observer/filing/0001437749-24-034922.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.